SOPHiA GENETICS (NASDAQ:SOPH) Upgraded to Hold at Zacks Research

Zacks Research upgraded shares of SOPHiA GENETICS (NASDAQ:SOPH) to a hold rating in a research note released on Tuesday,Zacks.com reports.

A number of other equities research analysts also recently commented on the company. BTIG Research reaffirmed a “buy” rating and set a $8.00 target price on shares of SOPHiA GENETICS in a report on Monday, June 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Friday, July 17th. Finally, HC Wainwright initiated coverage on shares of SOPHiA GENETICS in a research note on Monday. They set a “buy” rating and a $12.00 price objective for the company. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $9.00.

SOPHiA GENETICS Price Performance

NASDAQ SOPH opened at $6.40 on Tuesday. The stock’s fifty day moving average price is $5.34 and its 200 day moving average price is $5.06. SOPHiA GENETICS has a 1 year low of $2.92 and a 1 year high of $6.77. The company has a debt-to-equity ratio of 1.05, a current ratio of 2.06 and a quick ratio of 1.90. The company has a market cap of $536.90 million, a price-to-earnings ratio of -12.31 and a beta of 0.96.

SOPHiA GENETICS (NASDAQ:SOPH) last posted its quarterly earnings results on Tuesday, May 5th. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.04). The firm had revenue of $21.69 million for the quarter, compared to analysts’ expectations of $20.40 million. SOPHiA GENETICS had a negative net margin of 44.48% and a negative return on equity of 62.74%. As a group, equities research analysts forecast that SOPHiA GENETICS will post -0.58 earnings per share for the current year.

Insiders Place Their Bets

In other news, insider Zhenyu Xu sold 7,393 shares of the company’s stock in a transaction that occurred on Monday, July 6th. The stock was sold at an average price of $5.17, for a total transaction of $38,221.81. Following the completion of the transaction, the insider directly owned 614,887 shares of the company’s stock, valued at $3,178,965.79. This represents a 1.19% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CTO Abhimanyu Verma sold 5,285 shares of SOPHiA GENETICS stock in a transaction on Monday, July 6th. The shares were sold at an average price of $5.10, for a total transaction of $26,953.50. Following the completion of the sale, the chief technology officer directly owned 192,171 shares in the company, valued at $980,072.10. This represents a 2.68% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders sold 176,711 shares of company stock valued at $959,913. 4.88% of the stock is owned by insiders.

Institutional Trading of SOPHiA GENETICS

A number of hedge funds have recently bought and sold shares of SOPH. Perkins Capital Management Inc. purchased a new stake in shares of SOPHiA GENETICS in the fourth quarter valued at about $49,000. Squarepoint Ops LLC purchased a new stake in shares of SOPHiA GENETICS in the 3rd quarter valued at approximately $49,000. First Dallas Securities Inc. acquired a new stake in shares of SOPHiA GENETICS during the 1st quarter worth approximately $50,000. Quadrature Capital Ltd acquired a new stake in shares of SOPHiA GENETICS during the 4th quarter worth approximately $54,000. Finally, XTX Topco Ltd purchased a new stake in shares of SOPHiA GENETICS during the 4th quarter valued at approximately $55,000. Institutional investors and hedge funds own 31.59% of the company’s stock.

Key SOPHiA GENETICS News

Here are the key news stories impacting SOPHiA GENETICS this week:

• Positive Sentiment: HC Wainwright kept a Buy rating on SOPHiA GENETICS SA (NASDAQ: SOPH) and a $12 price target, signaling meaningful upside versus the current trading level. The firm’s model also forecasts the company moving toward profitability later in the decade.
• Positive Sentiment: The company’s CEO highlighted how AI could personalize patient therapies, reinforcing the growth narrative around SOPHiA GENETICS’ core technology and potentially supporting investor confidence in its long-term market opportunity. Article Title
• Neutral Sentiment: SOPHiA GENETICS said it will report second-quarter 2026 results on August 4. Upcoming earnings often keep a stock active, but this announcement is mainly a timing update rather than a business development. Article Title
• Neutral Sentiment: Zacks Research upgraded SOPHiA GENETICS to Hold, which is a small positive from a sentiment standpoint but not a strong enough signal to imply major near-term upside. Read More: Read More.
• Negative Sentiment: HC Wainwright’s estimates still show continued losses in 2026 and 2027, including full-year 2026 EPS of -$0.58 and full-year 2027 EPS of -$0.20. That highlights the company’s ongoing path-to-profitability risk, even with bullish long-term forecasts.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.